This paper summarizes the industry position and aims to start a strategic discussion on this situation. It will help ensure we have a common language and understanding across industry. Looking ahead, we will emphasize shared learning, best practices, and retrospective investigations to improve long-range planning processes
Viewing related articles
A BioPhorum member survey to gather preliminary information from across the biopharmaceutical industry on the characterization and risk assessment of HCP using mass spectrometry.
A BioPhorum member only survey to share knowledge into how, why and when enzymatic activity assays are performed.
BioPhorum member only benchmarking exercise seeking member experience on expectations for mycoplasma testing of cell therapies.
BioPhorum member benchmarking survey on testing strategies for AAV and LVV empty, full and partially filled capsids.
A BioPhorum member survey examining approaches to testing allogenic cell therapies for adventitious viral contaminants.
A BioPhorum member only survey to understand viral purification and clearance practices member companies are undertaking in CGT.
A BioPhorum member only survey is to gather information to benchmark what analytical controls member companies are currently using to establish methods to test identity, strength, potency and purity.
A BioPhorum member only benchmarking survey to understand the current challenges and strategies undertaking regarding leveraging process characterization data/use of platforms to accelerate validation.
This article and template summarize the main steps in a suggested EHS risk assessment process and can form the basis for discussions between a contract manufacturer and client or between production and development departments.